Drugs Made In America Acquisition (DMAA) Stock Price, News & Analysis

Company Overview

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination. The management team brings together professionals with backgrounds in healthcare, life sciences and investment banking, aiming to leverage their combined expertise to target companies that address supply‐chain resilience and onshore production of critical prescription medications. The company is headquartered in New York and serves as a vehicle for investors seeking exposure to the U.S. pharmaceutical manufacturing industry.

Since its initial public offering on the Nasdaq Stock Market, Drugs Made In America Acquisition has been evaluating potential transaction candidates across the United States and is working toward identifying a suitable partner that aligns with its goal of bolstering domestic drug production capabilities. Pending the closing of a qualifying business combination, the SPAC will continue to operate under regulatory guidelines governing blank‐check companies and pursue opportunities intended to create long‐term shareholder value through a combination that reinforces American pharmaceutical independence.

Key Stats

• Today's Range: $10.60 to $10.60
• 50-Day Range: $10.47 to $10.61
• 52-Week Range: $10.12 to $10.60
• Volume: 1,057 shs
• Average Volume: 119,541 shs
• Market Capitalization: $257.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Drugs Made In America Acquisition Stock Analysis - MarketRank™

Drugs Made In America Acquisition scored higher than 23% of companies evaluated by MarketBeat, and ranked 63rd out of 93 stocks in the financial services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Drugs Made In America Acquisition has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Drugs Made In America Acquisition has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.31% of the float of Drugs Made In America Acquisition has been sold short.

Short Interest Ratio / Days to Cover

Drugs Made In America Acquisition has a short interest ratio ("days to cover") of 0.64, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Drugs Made In America Acquisition has recently decreased by 92.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Drugs Made In America Acquisition does not currently pay a dividend.

Dividend Growth

Drugs Made In America Acquisition does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Drugs Made In America Acquisition has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Financial Services companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Drugs Made In America Acquisition this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Drugs Made In America Acquisition insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.90% of the stock of Drugs Made In America Acquisition is held by insiders.

Percentage Held by Institutions

Drugs Made In America Acquisition has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Financial Services
• Industry: Investment Offices
• Sub-Industry: Trading
• Current Symbol: NASDAQ:DMAA
• CIK: 2028614
• Web: N/A
• Phone: (954) 870-3104
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 24,280,000
• Free Float: 24,059,000
• Market Cap: $257.25 million
• Optionable: N/A
• Beta: 0.01